Regulatory filing 📈 Stocks 🌍 Hong Kong

Sipai Health Technology Appoints Li Ji as CEO Effective November 20, 2026

Sipai Health Technology separates the roles of Chairman and CEO to improve corporate governance, appointing Li Ji as CEO and Ma Xuguang as President, effective November 20, 2026.

🕐 1 min read 📰 HKEX

1 assets impacted. Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: 0314.HK → 2/10 (75% confidence).

📊 Affected Assets (1)

0314.HK
Neutral 🤖 75%
📅 Short-term 🌍 HK · Explicit

Mr. Ma Xuguang ceases to be CEO from November 20, 2026 and becomes President while remaining Chairman; Mr. Li Ji takes over as CEO. This is a role swap that brings the company into compliance with Corporate Governance Code Provision C.2.1 (separating Chairman and CEO roles). Both men remain executive Directors, confirmed no disagreement with the Board, and no shareholder matter was flagged, so fundamentals and leadership continuity are unchanged.

Catalysts
  • • Effective November 20, 2026: Mr. Li Ji appointed CEO, Mr. Ma Xuguang becomes President while staying Chairman
  • • Company states it is now in full compliance with Corporate Governance Code Provision C.2.1
Risk Factors
  • • Both executives jointly hold 104,280,000 shares, about 13.6% of issued share capital, so control is unchanged
  • • No change in remuneration or strategy disclosed; announcement is procedural

🎯 Key Takeaways

  • Mr. Li Ji assumed the role of CEO on November 20, 2026, while Mr. Ma Xuguang transitioned to President and remains Chairman.
  • The leadership change ensures full compliance with Corporate Governance Code Provision C.2.1 regarding the separation of Chairman and CEO roles.
  • Mr. Ma and Mr. Li jointly hold 104,280,000 shares, representing approximately 13.6% of the company's issued share capital.
  • Both executives confirmed there is no disagreement with the Board regarding the change in executive functions.

📝 Executive Summary

Sipai Health Technology has restructured its executive leadership to align with the Corporate Governance Code. Effective November 20, 2026, Mr. Li Ji has been appointed as CEO, while Mr. Ma Xuguang transitions to the role of President while retaining his position as Chairman of the Board.

❓ FAQ

Is there a leadership crisis or disagreement at Sipai Health?

No. The announcement states both Mr. Ma and Mr. Li confirmed they have no disagreement with the Board, and both remain executive directors leading the company in new roles.

Why did the CEO role change?

For segregation of duties, better corporate governance and alignment with the Listing Rules' Corporate Governance Code, so the Chairman and CEO roles are now held by different people (Mr. Ma as Chairman, Mr. Li as CEO) effective November 20, 2026.